Granules India
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
 | |
| Company type | Public |
|---|---|
| BSE: 532482 NSE: GRANULES | |
| Industry | Pharmaceuticals |
| Founded | 1984 |
| Founder | Mr. C. Krishna Prasad |
| Headquarters | Hyderabad, India |
Area served | Worldwide |
Key people | C. Krishna Prasad (CMD) Harsha Chigurupati (ED) VVS Murthy (CFO) Madhusudhan Rao (COO) Stefan Lohle (CMO) |
| Products | Paracetamol, Ibuprofen, Methocarbamol, Metformin, Guaifenesin, etc. |
| Revenue | FY 2016-17 INR 1,445 Crore |
| FY 2016-17 INR 164 Crore | |
Number of employees | 2165 |
| Website | www.granulesindia.com |
Granules India Limited is an Indian pharmaceutical manufacturing company based in Hyderabad, India. Granules manufactures several off-patent drugs, including Paracetamol, Ibuprofen, Metformin and Guaifenesin, on a large scale for customers in the regulated and semi-regulated markets.[1][2]
History
Granules India was formed in 1984 as Triton Laboratories. Triton produced Paracetamol API at its Bonthapally factory on the outskirts of Hyderabad.[3] Triton scientists found a more efficient way to produce the Paracetamol API, which led to lower capital and raw material requirements.[citation needed] In 1987, Triton became the only Indian company aside from Dr. Reddy’s Laboratories to export pharmaceutical products to the U.S.[citation needed]
Though Triton was growing as an API manufacturer, management decided it could create a value added version of its product.[citation needed] In order to distinguish itself from competitors, Triton management pioneered the concept of manufacturing and selling in bulk granulated Paracetamol, also known as direct compressible grade material (DC), or "PFI".[citation needed] In 1990, it opened its second manufacturing facility at Jeedimetla to produce multiple APIs.
In 1991,[4] management set up a new entity, which was incorporated as Granules India Limited. Soon after Granules applied the PFI concept to other APIs, set up a PFI facility at Jeedimetla and began exporting the material to various markets including the U.S., Germany and Australia.[5]
In 1995,[4] Granules became a public company, after having initial public offerings on the Bombay and Hyderabad Stock Exchanges.[6]
In order to secure API for its Ibuprofen PFI, Granules formed a joint-venture with Hubei Biocause Heilen Pharmaceutical to create Granules Biocause in Wuhan, China.[7]
Infrastructure
Granules has seven manufacturing facilities; six are in India while the seventh is through a joint-venture with Hubei Biocase in Wuhan, China. The company also has two research centres, at Hyderabad and Pune.
The Gagillapur facility is located near Hyderabad and has a Finished Dosage block, a PFI block and a research & development facility.[citation needed]
Granules commissioned the world’s single largest PFI plant in Gagillapur in August 2003 with a batch size of 6 MT and an annual capacity of 7,200 MT per annum. The plant received its US FDA approval within six months of commissioning.[citation needed]
See also
References
- ^ "Granules India signs deal with Matchland Pty Ltd".
- ^ "Granules India". Moneycontrol.com. 10 May 2007. Retrieved 10 December 2009.
- ^ "Triton Laboratories Ltd Company info".
- ^ a b "Granules India Limited - About Us - Milestones". Granulesindia.com. Retrieved 30 September 2010.
- ^ "Granules ties up with GSK Healthcare R&D".
- ^ "Granules, Amneal Pharma get FDA nod". Business Standard. 2 August 2006. Retrieved 10 December 2009.
- ^ "Granules India takes stake in Chinese firm". In-pharmatechnologist.com. Retrieved 30 September 2010.